<DOC>
	<DOCNO>NCT00017459</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know cisplatin vinorelbine effective without tirapazamine treat non-small cell lung cancer PURPOSE : Randomized phase III trial compare effectiveness cisplatin plus vinorelbine without tirapazamine treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Cisplatin Plus Vinorelbine With Without Tirapazamine Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival duration patient stage IIIB IV non-small cell lung cancer treat vinorelbine cisplatin without tirapazamine . II . Compare complete partial response rate , time disease progression , time treatment failure patient treat regimen . III . Compare clinical benefit regimen , term performance status body weight , patient . IV . Compare toxicity safety regimens patient . V. Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . Arm I : Patients receive tirapazamine IV 2 hour follow cisplatin IV 1 hour day 1 . Patients also receive vinorelbine IV 6-10 minute day 1 , 8 , 15 , 22 . Arm II : Patients receive cisplatin vinorelbine arm I . Treatment repeat every 28 day total 6 course absence disease progression unacceptable toxicity . Quality life assess baseline , course treatment , 30 day last course treatment , every 8 week 2-3 year . Patients follow every 8 week 2-3 year . PROJECTED ACCRUAL : Approximately 800 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIB IV Newly diagnose recurrent disease Measurable lesion At least 10 mm spiral CT scan OR At least 20 mm conventional technique Previously irradiate lesion consider measurable provide progress appeared completion radiotherapy The following consider nonmeasurable : Pleural pericardial effusion Cystic lesion Lymphangitis pulmonis Bony xray abnormalities Abnormal scan nonmeasurable fill defect No symptomatic brain metastasis CNS involvement CT scan MRI PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine normal Other : No malignancy within past 5 year except adequately treat carcinoma situ cervix basal cell carcinoma likely recur No history allergic reaction diuretic antiemetic ( e.g. , 5HT3 antagonist ) use study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy biologic therapy NSCLC Chemotherapy : No prior chemotherapy NSCLC No prior platinumbased chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy potential indicator lesion ( ) At least 4 week since prior radiotherapy recover Surgery : Recovered prior surgical procedure ( ) Other : At least 30 day since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>